Warner Chilcott (NASDAQ: WCRX)‘s stock had its “buy” rating reaffirmed by research analysts at Canaccord Genuity in a report released on Monday.
Warner Chilcott traded up 1.60% on Monday, hitting $22.16. Warner Chilcott has a 52-week low of $12.90 and a 52-week high of $25.92. The company has a market cap of $5.525 billion and a price-to-earnings ratio of 32.55.
The company last announced its quarterly results on Friday, February 24th. It reported $0.95 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.90 EPS by $0.05. The company’s quarterly revenue was down 7.0% on a year-over-year basis. Analysts expect that Warner Chilcott will post $0.91 EPS next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at Auriga initiated coverage on shares of Warner Chilcott in a research note to investors on Tuesday, April 17th. They set a “hold” rating and a $16.00 price target on the stock. Separately, analysts at Oppenheimer (NYSE: OPY) initiated coverage on shares of Warner Chilcott in a research note to investors on Friday, March 16th. They set an “outperform” rating and a $700.00 price target on the stock. Finally, analysts at Cantor Fitzgerald initiated coverage on shares of Warner Chilcott in a research note to investors on Thursday, March 15th. They set a “buy” rating and a $18.00 price target on the stock.
Warner Chilcott PLC, formerly Warner Chilcott Limited, is a Bermuda-based specialty pharmaceutical company focused on the women’s healthcare and dermatology segments of the United States pharmaceutical market.